Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1987 1
1989 1
1990 2
1992 1
1994 1
1995 1
1996 1
1998 1
2000 1
2002 2
2003 4
2004 1
2005 2
2006 5
2007 5
2008 5
2009 9
2010 4
2011 2
2012 1
2013 6
2014 7
2015 5
2016 8
2017 4
2018 10
2019 7
2020 9
2021 9
2022 7
2023 6
2024 5
2025 3
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

127 results

Results by year

Filters applied: . Clear all
Page 1
Erratum.
[No authors listed] [No authors listed] Expert Rev Hematol. 2015 Oct;8(5):701. doi: 10.1586/17474086.2015.1088180. Expert Rev Hematol. 2015. PMID: 26343895
Correction to: Decision-making in the management of adult classical Hodgkin's lymphoma: determining the optimal treatment. Nicolas M, Christian G. Decision-making in the management of adult classical Hodgkin's lymphoma: determining the optimal treatment. ...The name of the …
Correction to: Decision-making in the management of adult classical Hodgkin's lymphoma: determining the optimal treatment. Nicolas M, …
Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study.
Cartron G, Bachy E, Tilly H, Daguindau N, Pica GM, Bijou F, Mounier C, Clavert A, Damaj GL, Slama B, Casasnovas O, Houot R, Bouabdallah K, Sibon D, Fitoussi O, Morineau N, Herbaux C, Gastinne T, Fornecker LM, Haioun C, Launay V, Araujo C, Benbrahim O, Sanhes L, Gressin R, Gonzalez H, Morschhauser F, Ternant D, Xerri L, Tarte K, Pranger D. Cartron G, et al. J Clin Oncol. 2023 Jul 1;41(19):3523-3533. doi: 10.1200/JCO.22.02327. Epub 2023 Apr 18. J Clin Oncol. 2023. PMID: 37071836 Free article. Clinical Trial.
METHODS: Patients with histologically confirmed CD20(+) low-tumor burden FL were randomly assigned to receive either rituximab, 375 mg/m(2) once daily on D1, D8, D15, and D22, intravenous route (IV, control arm), or rituximab, 375 mg/m(2), on day 1 (D1), IV followed …
METHODS: Patients with histologically confirmed CD20(+) low-tumor burden FL were randomly assigned to receive either rituximab, 375 mg/m …
AMPK in skeletal muscle function and metabolism.
Kjøbsted R, Hingst JR, Fentz J, Foretz M, Sanz MN, Pehmøller C, Shum M, Marette A, Mounier R, Treebak JT, Wojtaszewski JFP, Viollet B, Lantier L. Kjøbsted R, et al. FASEB J. 2018 Apr;32(4):1741-1777. doi: 10.1096/fj.201700442R. Epub 2018 Jan 5. FASEB J. 2018. PMID: 29242278 Free PMC article. Review.
-Kjobsted, R., Hingst, J. R., Fentz, J., Foretz, M., Sanz, M.-N., Pehmoller, C., Shum, M., Marette, A., Mounier, R., Treebak, J. T., Wojtaszewski, J. ...
-Kjobsted, R., Hingst, J. R., Fentz, J., Foretz, M., Sanz, M.-N., Pehmoller, C., Shum, M., Marette, A., Mounier, …
Tracheobronchomegaly, cough and recurrent chest infection: Mounier-Kuhn syndrome.
Satia I, Dua B, Singh N, Killian K, O'Byrne PM. Satia I, et al. ERJ Open Res. 2020 Jun 29;6(2):00138-2020. doi: 10.1183/23120541.00138-2020. eCollection 2020 Apr. ERJ Open Res. 2020. PMID: 32613017 Free PMC article.
Mounier-Kuhn Syndrome (MKS) is a rare disease characterised by recurrent chest infections, and dilation of the trachea and main bronchi, most likely to due to atrophy of elastic fibres https://bit.ly/3azhDjr....
Mounier-Kuhn Syndrome (MKS) is a rare disease characterised by recurrent chest infections, and dilation of the trachea and main bronc …
Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach.
des Rieux A, Fievez V, Garinot M, Schneider YJ, Préat V. des Rieux A, et al. J Control Release. 2006 Nov;116(1):1-27. doi: 10.1016/j.jconrel.2006.08.013. Epub 2006 Aug 23. J Control Release. 2006. PMID: 17050027 Review.
In particular, the influence of size and surface properties on their non-specific uptake or their targeted uptake by enterocytes and/or M cells is discussed. Enhancement of their uptake by appropriate cells, i.e. M cells by (i) modeling surface properties to optimiz …
In particular, the influence of size and surface properties on their non-specific uptake or their targeted uptake by enterocytes and/or M …
127 results